Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Trial of the Dopamine-B-Hydroxylase (DBH) Inhibitor, Nepicastat, for the Treatment of PTSD in OIF/OEF Veterans

NCT00659230 is registered in ClinicalTrials.gov with Tuscaloosa Research & Education Advancement Corporation as lead sponsor.

NCT NCT00659230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00659230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Trial of the Dopamine-B-Hydroxylase (DBH) Inhibitor, Nepicastat, for the Treatment of PTSD in OIF/OEF Veterans
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2009
Completion date
August 30, 2012
Enrollment
100 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

posttraumatic stress disorder